Evaluate Pharma is the industry's reference for consensus forecasts. Its own product page describes it as "the definitive source of consensus forecasts", with "almost 6,000 drugs" covered and "over 1.5m consensus forecasts for 10,000 products dating back to 2003 and product sales back to 1986."1 That surface is where sell-side analysts, BD teams, and consultancies set the revenue expectation for a molecule. The sourcing question underneath, who actually ships this API, on what lane, at what concentration, with what compliance trail, is a different surface. PharmaDB is the answer there. One independent review captures the split plainly: Evaluate "focuses on product- and company-level data rather than patient-level data", and users note it "emphasizes top-line sales and pipeline rather than granular metrics like pricing or patient outcomes."2
Enterprise quote, no published rate card. The Evaluate site routes prospective buyers through a contact form rather than a pricing page, and independent reviews describe the platform as "a strategic/financial tool rather than an operational one" typically priced into enterprise-tier subscriptions alongside the rest of the Norstella suite (Citeline, MMIT, Panalgo, The Dedham Group).3,4 Coverage depends on which modules are entitled: Evaluate Pharma, Evaluate Omnium, Evaluate Epi, Evaluate Medtech, Biomedtracker, Datamonitor Healthcare, and the FC+ and FC365 forecasting platforms are sold as separate solutions.5
Published banded rate card. Lookup fees banded by how many graph queries the agent fires inside a run: $0.20 under 10 lookups, $0.50 for 10 to 50, capped at $1.00 per run for 50+. AI usage at 20% over Anthropic's published rates, line by line in your chat. $100 minimum top-up, credits valid 12 months. Pro tier $5,000 a year covers both lookups and AI, plus watchlist, export, and a forthcoming API. Numbers on the page before the conversation.
Evaluate Pharma's named data domains are sales, consensus forecasts, pipeline, deals, financials, and company benchmarks. Its product page lists "comprehensive coverage of sales, deals and financials, including pipeline data and content from exclusive broker relationships", with the ability to "link consensus forecasts directly to the pipeline to allow quick analysis of forecasts at indication, therapeutic area and MOA (mechanism of action) levels."6 NorstellaLinQ integrates the wider Norstella family by linking "pipeline data (Citeline) with commercial forecasts (Evaluate)" across "over 74 billion data points."7 Trade flows flows, exporter shares per lane, FDA 483 or import-alert trajectories, and median USD per kilogram percentiles are not named as data domains across these pages.1,6,7
Trade flows joined to FDA Type II DMF and EDQM CEP registers, plant inspections, warning letters, and import alerts. Lane-level HHI, top-3 exporter share, active-exporter counts, and median USD per kilogram percentiles are first-class objects in the graph.
Evaluate Pharma is built for, in its own words, three segments: "Biotech & Pharma" commercial teams in "Business Development & Licensing, Corporate Strategy, and Competitive Intelligence"; consultancies using it as "a single source for strategic advice"; and "investment banks, private equity, and venture capital firms" using it "to support their investment decision-making."1 Independent analysis describes the workflow as "strategic/financial" with users noting it "may lag real-time events or emerging trial results" because the data is consensus-based and curated.2
API procurement, BD sourcing, supply continuity, finance pre-RFQ. The workflow is "qualify this lane, this quarter, before we issue the order." The buyer is upstream of the revenue forecast, not downstream of it: the person deciding which exporter actually carries the order against an open generic window.
Evaluate Pharma forecasts the commercialised side of semaglutide: Ozempic at $24.4 billion, Wegovy at $18.1 billion, and projects GLP-1 drugs to "have five of the top 10 slots on the best-sellers list by 2030" with total prescription drug sales reaching $1.75 trillion.8,9 Below is the sourcing-side picture for the same molecule, surfaced from PharmaDB's warehouse: who is filing DMFs, who is exporting on the India to US lane, and how concentrated that lane currently is. Same molecule, orthogonal depth.
Semaglutide had 75 US DMF filings as of mid-2025, the highest of any API that quarter,10 but the India to US export lane is still concentrated among a small cohort: the top three exporters move ~78% of declared inbound value, and the lane HHI sits well inside the DOJ "highly concentrated" zone. Evaluate Pharma tells you the revenue waiting on the other side of patent expiry; PharmaDB tells you which exporter cohort can actually carry the order when the generic window opens.
No. They cover different surfaces. Evaluate is the consensus-forecast and deal-comp record, "the definitive source of consensus forecasts" for sell-side analysts, BD teams, and consultancies.1 PharmaDB is the sourcing graph underneath: customs, exporter cohorts, plant inspections, dossier registers. Teams that need both run both.
Across the Evaluate Pharma, Evaluate Omnium, and NorstellaLinQ product pages, the named data domains are sales, consensus forecasts, pipeline, deals, financials, company benchmarks, and clinical pipeline.1,5,7 Trade flows flows, exporter shares per lane, lane HHI and top-3 share, plant inspection trajectories, warning letter and import-alert overlays, and median USD per kilogram percentiles are not named on those pages. PharmaDB ships those as first-class objects. One independent guide observes that Evaluate "focuses on product- and company-level data rather than patient-level data" and that users note it "emphasizes top-line sales and pipeline rather than granular metrics like pricing or patient outcomes."2
Evaluate is sold by enterprise quote with annual contracts; pricing is not published on the site and routes through a sales conversation, typically alongside other Norstella modules.3 PharmaDB is consumption-based: $0.20 per run starting band, $1.00 maximum per run on lookups, plus AI usage at 20% over Anthropic's published rates. $100 minimum top-up, credits valid 12 months. Pro is $5,000 a year covering both lookups and AI, plus watchlist, export, and API.
Evaluate Pharma. It is explicitly built for "investment banks, private equity, and venture capital firms" using it "to support their investment decision-making", with consensus forecasts for almost 6,000 drugs and 1.5m forecasts dating back to 2003.1 PharmaDB only becomes relevant when a procurement question sits downstream of the forecast: which generic exporter will actually carry the post-LOE volume, and at what concentration.
Cleanly. Evaluate sizes the revenue waiting on the other side of an LOE window. PharmaDB tells you whether the supply behind that window can actually carry an order: DMF count, active exporter cohort, lane HHI, plant inspection trajectory. The semaglutide example on this page is the canonical stack: Evaluate forecasts $24.4 billion for Ozempic in 2030; PharmaDB shows the 75 active US DMFs and the current India to US exporter concentration.8,10
There isn't one, because there isn't a switch. PharmaDB sits alongside; the cost is the per-run rate on the questions it newly answers. A common entry pattern is a $100 PAYG top-up against one live sourcing question, run in parallel with the existing Evaluate subscription, before deciding whether Pro is justified.
Book a 30-minute call. Bring three sourcing questions. We'll run them on the live data with you. No top-up needed, and you keep whatever we find.